1149PResults of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Oncology

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDX376.014
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next

  2026cites this paper
• The landscape of genitourinary cancer vaccines: clinical advances and future opportunities.

  2025cites this paper
• RNA vaccines for cancer: revolutionizing immunization strategies.

  2025cites this paper
• Advances of mRNA vaccines in genitourinary cancers.

  2025cites this paper
• Unraveling the potential: mRNA therapeutics in oncology

  2025cites this paper
• Eliciting antitumor immunity via therapeutic cancer vaccines

  2025cites this paper
• mRNA-Impfungen gegen Krebs

  2025cites this paper
• Synergistic targeting strategies for prostate cancer

  2025cites this paper
• mRNA vaccines for prostate cancer: A novel promising immunotherapy.

  2025cites this paper
• Targeting the tumour cell surface in advanced prostate cancer

  2025cites this paper
• The Bright Future of mRNA as a Therapeutic Molecule

  2025cites this paper
• mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy

  2025cites this paper
• Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches

  2025cites this paper
• Clinical advances of mRNA vaccines for cancer immunotherapy.

  2025cites this paper
• Cancer vaccines: current status and future directions

  2025cites this paper
• Tumor-associated antigen targets for novel immune-based strategies in prostate cancer

  2024cites this paper
• Are we getting closer to a successful neoantigen cancer vaccine?

  2024cites this paper
• Research progress of MUC1 in genitourinary cancers

  2024cites this paper
• Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook

  2024cites this paper
• mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues

  2023cites this paper
• Advances, opportunities and challenges in developing therapeutic cancer vaccines.

  2023cites this paper
• Les perspectives de l’ARN messager en oncologie

  2023cites this paper
• Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer

  2023cites this paper
• Vaccines as treatments for prostate cancer

  2023cites this paper
• Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?

  2022cites this paper
• The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines

  2022cites this paper
• Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

  2022cites this paper
• mRNA vaccines in the prevention and treatment of diseases

  2022cites this paper
• STEAP1–4 (Six-Transmembrane Epithelial Antigen of the Prostate 1–4) and Their Clinical Implications for Prostate Cancer

  2022cites this paper
• Resistance to prostate cancer treatments

  2022cites this paper
• Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine

  2021cites this paper
• mRNA therapeutics in cancer immunotherapy

  2021cites this paper
• Immunotherapy in prostate cancer: current state and future perspectives

  2020cites this paper
• Breakthrough concepts in immune‐oncology: Cancer vaccines at the bedside

  2020cites this paper
• Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer.

  2020cites this paper
• Immunotherapy in Advanced Prostate Cancer

  2020cites this paper
• Emerging therapeutic targets for patients with advanced prostate cancer.

  2019cites this paper